Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer


The content, links, and pdfs are no longer maintained and might be outdated.

  • The content on this page is being archived for historic and reference purposes only.
  • For current, updated information see the MMWR website.

Appendix C

Selected Proficiency Testing Programs and Interlaboratory Sample Exchange Programs for Molecular Genetic Testing for Heritable Diseases and Conditions

College of American Pathologists (CAP)*

Proficiency Testing

Sample type: purified DNA

  • BRCA1 and BRCA2 genes (familial breast and ovarian cancer)
  • Canavan disease
  • Nonsyndromic hearing loss and deafness (GJB2- [connexin 26-]related DFNA 3)
  • Cystic fibrosis
  • Duchenne muscular dystrophy, Becker muscular dystrophy
  • Factor V Leiden thrombophilia
  • Familial dysautonomia
  • Fragile X syndrome
  • Friedreich ataxia
  • Hereditary hemochromatosis
  • Sickle cell disease
  • Huntington disease
  • MTHFR (5,10-methylenetetrahydrofolate reductase gene)
  • Multiple endocrine neoplasia type 2 (RET gene)
  • Myotonic dystrophy
  • Prader-Willi syndrome, Angelman syndrome
  • Prothrombin thrombophilia
  • RHD genotyping
  • Spinal muscular atrophy
  • Spinocerebellar ataxia
  • Tay-Sachs disease

Pharmacogenetic Proficiency Testing

Sample type: purified DNA

  • CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9 gene)
  • CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19 gene)
  • CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6 gene)
  • UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1 gene) (Gilbert syndrome)
  • VKORC1 (vitamin K epoxide reductase complex, subunit 1 gene)

CDC Newborn Screening Quality Assurance Program

Proficiency Testing

Sample type: dried blood spots

Proficiency testing is available for DNA-based detection of cystic fibrosis mutations

EuroGentest§

External Quality Assessment

Sample types: blood spots, purified DNA, lyophilized human blood plasma, and serum

External quality assessments are similar to proficiency testing in the United States. Assessments are provided by one or more individual programs in Europe and facilitated by EuroGentest.

  • ACE (angiotensin-converting enzyme gene)
  • Adenomatous polyposis of the colon (APC gene)
  • Congential adrenal hyperplasia
  • Alpha-1 antitrypsin inhibitor
  • ApoB-100 (apolipoprotein B-100) genotyping
  • ApoE (apolipoprotein E); ApoE2, ApoE3, ApoE4
  • BRCA1 and BRCA2 genes (familial breast and ovarian cancer)
  • CETP (cholesteryl ester transfer protein) genotyping
  • Charcot-Marie-Tooth disease
  • Cystic fibrosis
  • Duchenne muscular dystrophy, Becker muscular dystrophy
  • Factor V Leiden thrombophilia
  • Factor XIII deficiency
  • Fragile X syndrome
  • Friedreich ataxia
  • GP IIb/IIIa (glycoprotein IIb genotyping)
  • Hemophilia A (factor VIII)
  • Hemophilia B (factor IX)
  • Hereditary hemochromatosis (HFE)
  • Hereditary nonpolyposis colon cancer (HNPCC)
  • Huntington disease (HD gene)
  • Lactose intolerance
  • Maturity onset diabetes of the young (MODY)
  • Mitochondrial disorders
  • MTHFR (5,10-methylenetetrahydrofolate reductase gene)
  • Multiple endocrine neoplasia type 2 (MEN 2)
  • Myotonic dystrophy
  • Phenylketonuria
  • Plasminogen activator inhibitor gene (PAI-1)
  • Prader-Willi syndrome, Angelman syndrome
  • Prothrombin thrombophilia
  • Retinoblastoma
  • Spinal muscular atrophy
  • Spinocerebellar ataxia
  • Thalassaemia, alpha and beta
  • TPMT (thiopurine S-methyltransferase gene)
  • UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1 gene)
  • Variegate porphyria
  • von Hippel-Lindau syndrome
  • von Willebrand disease
  • Wilson disease
  • Y chromosome microdeletions (AZF and DAZ genes)

Pharmacogenetic External Quality Assessment

  • BCHE (butyrylcholinesterase gene)
  • CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6 gene)
  • GHR (growth hormone receptor)
  • UGT1A6 (UDP glucuronosyltransferase 1 family, polypeptide A6 gene)

Methodological External Quality Assessment

  • DNA sequencing
  • Mutation scanning
  • Qualitative polymerase chain reaction

CAP Registry Service for Genetic Testing

Interlaboratory Exchange

The CAP registry service is an Internet-based service that facilitates contact among genetic testing laboratories that perform less frequently performed genetic tests. Laboratories enroll online; when CAP identifies three laboratories that are testing for the same genetic disorder, CAP facilitates communication for making exchange arrangements. The CAP/ACMG Biochemical and Molecular Genetics Committee reviews the results and procedures and makes comments in the Molecular Genetics Survey's Participant Summary Report regarding the overall performance.

Association for Molecular Pathology (AMP)**

Interlaboratory Exchange

AMP facilitates sample exchanges between laboratories through the AMP listserv (CHAMP). Laboratories seeking others to evaluate performance on specific analytes contact one another via the listserv. Laboratories are responsible for establishing testing parameters and facilitating exchange of specimens and test results.

* College of American Pathologists. 2008 surveys & anatomic pathology education programs. Available at http://www.cap.org/apps/docs/proficiency_testing/surveys_catalog/2008_full_catalog.pdf.

CDC. Newborn Screening Quality Assurance Program; 2007. Available at http://www.cdc.gov/labstandards/nsqap.htm.

§ EuroGentest. Harmonizing genetic testing across Europe; 2008. Available at http://www.eurogentest.org/news/db/news/416/index.xhtml.

College of American Pathologists. Registry service for genetic testing. Available at http://www.cap.org.

** Association for Molecular Pathology. CHAMP listserv. Available at http://www.amp.org/membership/champ.htm.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.


References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Date last reviewed: 5/29/2009

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services